Adjuvant hormonal therapy for premenopausal women with breast cancer

被引：19

作者：

Brown, Regina J. ^{[1
]}

Davidson, Nancy E. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comperehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA

来源：

SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 06期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1053/j.seminoncol.2006.08.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Endocrine therapy is a required element of the management of premenopausal women with early-stage steroid hormone receptor-positive breast cancer. There is uncertainty about how best to implement that therapy using the strategies of tamoxifen and estrogen deprivation as well as how to integrate these approaches with chemotherapy. Other research focuses on identification of improved markers for endocrine response or resistance and on the special side effects of endocrine therapy in young women. © 2006 Elsevier Inc. All rights reserved.

引用

页码：657 / 663

页数：7

共 37 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? [J].

Aebi, S ;

Gelber, S ;

Castiglione-Gertsch, M ;

Gelber, RD ;

Collins, J ;

Thürlimann, B ;

Rudenstam, CM ;

Lindtner, J ;

Crivellari, D ;

Cortes-Funes, H ;

Simoncini, E ;

Werner, ID ;

Coates, AS ;

Goldhirsch, A .

LANCET, 2000, 355 (9218) :1869-1874

[3]

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy [J].

Arriagada, R ;

Lê, MG ;

Spielmann, M ;

Mauriac, L ;

Bonneterre, J ;

Namer, M ;

Delozier, T ;

Hill, C ;

Tursz, T .

ANNALS OF ONCOLOGY, 2005, 16 (03) :389-396

[4]

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study [J].

Baum, M. ;

Hackshaw, A. ;

Houghton, J. ;

Rutqvist ;

Fornander, T. ;

Nordenskjold, B. ;

Nicolucci, A. ;

Sainsbury, R. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) :895-904

[5]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[6]

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial [J].

Boccardo, F ;

Rubagotti, A ;

Amoroso, D ;

Mesiti, M ;

Romeo, D ;

Sismondi, P ;

Giai, M ;

Genta, F ;

Pacini, P ;

Distante, V ;

Bolognesi, A ;

Aldrighetii, D ;

Farris, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2718-2727

[7]

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial [J].

Castiglione-Gertsch, M ;

O'Neill, A ;

Price, KN ;

Goldhirsch, A ;

Coates, AS ;

Colleoni, M ;

Nasi, ML ;

Bonetti, M ;

Gelber, RD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (24) :1833-1846

[8]

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188) [J].

Davidson, NE ;

O'Neill, AM ;

Vukov, AM ;

Osborne, CK ;

Martino, S ;

White, DR ;

Abeloff, MD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5973-5982

[9]

Adjuvant endocrine therapy for premenopausal women with early breast cancer [J].

Dellapasqua, S ;

Colleoni, M ;

Gelber, RD ;

Goldhirsch, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) :1736-1750

[10]

Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers:: a prospective cohort study [J].

Domchek, SM ;

Friebel, TM ;

Neuhausen, SL ;

Wagner, T ;

Evans, G ;

Isaacs, C ;

Garber, JE ;

Daly, M ;

Eeles, R ;

Matloff, E ;

Tomlinson, GE ;

Van't Veer, L ;

Lynch, HT ;

Olopade, O ;

Weber, BL ;

Rebbeck, TR .

LANCET ONCOLOGY, 2006, 7 (03) :223-229

← 1 2 3 4 →